Through our Asian location we provide access to a unique natural resource for drug discovery: Endemic plants mostly collected in the tropical region of China.
Our state-of-the-art research and development facilities in Zhangjiang Hi-Tech Park, Shanghai cover all drug discovery NP services as well as lead optimization and medicinal chemistry services including synthesis and up-scale. This guarantees our clients a reliable, on-time and cost-effective outsourcing solution.
Our headquarters in the German biotechnology cluster Munich guarantee to our clients state-of-the-art process and technology management, absolute IP protection in drug development collaborations, easy communication within different time zones (Asia, EU, USA) and reliable, frequent report routines with western standards.
Our management team on both locations consists of experts with international business practice and renowned scientific experience.
Drug Discovery from Natural Products and Medicinal Chemistry
Bicoll is a biopharmaceutical company, offering pre-clinical support in the area of Drug Discovery from Natural Products and Medicinal Chemistry.
Dedicated to the discovery and optimization of the highest quality lead compounds, Bicoll provides an efficient, multi-disciplinary approach to drug discovery. With outstanding expertise in high tech natural product chemistry and validated experience in medicinal chemistry, Bicoll increases quality and quantity of the drug discovery pipeline of its partner's candidates portfolio.
Bicoll is offering a small molecule drug-like compound library from endemic Asian plants with enhanced probability of biological activity to its global clients in drug discovery and related innovative fields, like plant protection and nutraceuticals. A major technological focus is set on making compounds from natural resources (plants) compatible with the clients’ screening systems. The robust technology allows it to serve biological screening approaches (whole cell, whole organism) as well as biochemical high-throughput-screening set-ups (e.g. protein-protein interaction with FRET-read-out).
With further innovative strategies supported by its proprietary technology platform, Bicoll is able to rapidly select only the best leads with superior drug-like profiles for the further development cycles. Subsequent medicinal chemistry and custom synthesis complete Bicoll's seamless substantial services for the global pharmaceutical and biotech industries.
Bicoll GmbH was founded in 2000 in Munich, Germany with its wholly owned subsidiary Bicoll Biotechnology (Shanghai) Co. Ltd., P.R. China.
With our two locations we are able to guarantee significant value for our clients by strengthening the synergies inherent in our two operating segments Drug Discovery NP and MedChem/ Synthesis.
Bicoll currently employs more than 30 people at both locations.